SEC Company Response from Viewbix Inc. (VBIX) (CIK 0000797542) (QXL) — Jan 14, 2016
Viewbix Inc. (VBIX) (CIK 0000797542)
Date: Jan. 14, 2016 · CIK: 0000797542 · Accession: 0001295345-16-000413
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206105
Referenced dates: January 14, 2016
Letter
Re: Emerald Medical Applications Corp. Amendment No. 3 to Registration Statement on Form S-1 Filed January 7, 2016 File No. 333-206105
Emerald Medical Applications Corp.
7 Imber Street Petach Tikva, 4951141 IsraelJanuary 14, 2016
United States Securities and Exchange Commission Washington, D.C. 20549
Mail Stop 3561
Ladies and Gentlemen:
We are submitting this letter in response to the staff's comment letter dated January 14, 2016 addressed to Emerald Medical Applications Corp. (the "Registrant"). For the convenience of the staff, we have included each staff comment, numbered sequentially, followed by our response, also numbered sequentially.
Executive Compensation, page
Comment 1. Please revise to provide the information required by Item 402 of Regulation S-K for the fiscal year ended December 31, 2015. For guidance, refer to Question 117.05 of our Regulation S-K Compliance and Disclosure Interpretations.
Response 1. We have revised the disclosure under "Executive Compensation" to include the fiscal year ended December 31, 2015.
Respectfully
submitted,
/s/: Lior Wayn
Lior Wayn, Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm Emerald Medical Applications Corp. 7 Imber Street Petach Tikva, 4951141 IsraelJanuary 14, 2016 United States Securities and Exchange Commission Washington, D.C. 20549 Mail Stop 3561 Re: Emerald Medical Applications Corp. Amendment No. 3 to Registration Statement on Form S-1 Filed January 7, 2016 File No. 333-206105 Ladies and Gentlemen: We are submitting this letter in response to the staff's comment letter dated January 14, 2016 addressed to Emerald Medical Applications Corp. (the "Registrant"). For the convenience of the staff, we have included each staff comment, numbered sequentially, followed by our response, also numbered sequentially. Executive Compensation, page 84 Comment 1. Please revise to provide the information required by Item 402 of Regulation S-K for the fiscal year ended December 31, 2015. For guidance, refer to Question 117.05 of our Regulation S-K Compliance and Disclosure Interpretations. Response 1. We have revised the disclosure under "Executive Compensation" to include the fiscal year ended December 31, 2015. Respectfully submitted, /s/: Lior Wayn Lior Wayn, Chief Executive Officer